The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment | Zendy

Anders Helldén | Zendy; Jan Lycke | Zendy; Tatiana Vander | Zendy; JanOlof Svensson | Zendy; Ingegerd OdarCederlöf | Zendy; Lars Ståhle | Zendy

Open Access

The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment

Author(s) -

Anders Helldén,

Jan Lycke,

Tatiana Vander,

JanOlof Svensson,

Ingegerd OdarCederlöf,

Lars Ståhle

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl067

Subject(s) - valaciclovir , aciclovir , metabolite , medicine , pharmacology , virology , herpesviridae , virus , viral disease

Neuropsychiatric symptoms related to aciclovir or valaciclovir treatment have been a problem since aciclovir was introduced in the early 1980s. We have previously found that subjects with aciclovir-related neuropsychiatric symptoms have increased serum concentrations of aciclovir's main metabolite, 9-carboxymethoxymethylguanine (CMMG). The aim of this study was to investigate whether CMMG was present in the CSF of aciclovir- or valaciclovir-treated subjects with or without neuropsychiatric side effects that appeared during therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research